Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

263.38 +2.19 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,687,992
Open 269.00
Bid (Size) 261.50 (1)
Ask (Size) 263.91 (5)
Prev. Close 261.19
Today's Range 262.21 - 269.61
52wk Range 253.30 - 346.85
Shares Outstanding N/A
Dividend Yield 3.42%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With Amgen Stock On Friday?
Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers competitive weight loss with less frequent dosing. 
Via Benzinga
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily

Performance

YTD
-11.44%
-11.44%
1 Month
-9.15%
-9.15%
3 Month
-21.52%
-21.52%
6 Month
-17.22%
-17.22%
1 Year
-7.31%
-7.31%

More News

Read More
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Via Investor's Business Daily
10 Biggest Losers of The Dow Jones Index's 10-Day Losing Streak
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
Via Investor's Business Daily
Unpacking the Latest Options Trading Trends in Amgen
Via Benzinga
Demystifying Amgen: Insights From 13 Analyst Reviews
Via Benzinga
Is Amgen Still a Top Dividend Stock?
Via The Motley Fool
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
Via Investor's Business Daily
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Via Benzinga
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
Via The Motley Fool
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?
Via The Motley Fool
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Exposures US Equities
MarketBeat Week in Review – 12/2 - 12/6
Via MarketBeat
Topics Economy Government Immigration
Exposures Economy Immigration Interest Rates
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Via MarketBeat
13 Healthcare Sector Stocks With Healthy Valuation
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Via The Motley Fool
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
Via The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
Via The Motley Fool
Stock Market Hits Highs Despite Trump Tariff Threats, Nvidia, Tech Turkeys: Weekly Review
Via Investor's Business Daily
Topics Government
Exposures Political
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.